Business Times – Lifestyle
Author:
ALX Oncology
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
April 30, 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
April 28, 2026
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
April 13, 2026